<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02331472</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1220</org_study_id>
    <nct_id>NCT02331472</nct_id>
  </id_info>
  <brief_title>The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome (Pilot Study)</brief_title>
  <official_title>The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy of urine biomarker in patients with interstitial
      cystitis/painful bladder syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2015</start_date>
  <completion_date type="Actual">January 14, 2016</completion_date>
  <primary_completion_date type="Actual">January 14, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Difference of RNA expression of the urine biomarker between the interstitial cystitis and control groups</measure>
    <time_frame>1day</time_frame>
    <description>Difference of RNA expression of the urine biomarker between the interstitial cystitis and control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of RNA expression of the urine biomarker between Hunner ulcer interstitial cystitis and non-ulcer interstitial cystitis groups</measure>
    <time_frame>1day</time_frame>
    <description>Difference of RNA expression of the urine biomarker between Hunner ulcer interstitial cystitis and non-ulcer interstitial cystitis groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of RNA expression of the urine biomarker in interstitial cystitis according to pain score on the visual analogue scale</measure>
    <time_frame>1day</time_frame>
    <description>Difference of RNA expression of the urine biomarker in interstitial cystitis according to pain score on the visual analogue scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>Interstitial cystitis</arm_group_label>
    <description>Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Adult participants without history of interstitial cystitis/bladder pain syndrome</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA in urine specimen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Interstitial cystitis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. must have experienced bladder pain, urinary urgency and frequency for at least 6
             months prior to entry into the study

          2. Pain VAS &gt;4

          3. PUF score &gt;13

          4. ICQ score &gt;12

        4) cystoscopic record within 2years

        Exclusion Criteria:

          1. Patients who are pregnancy or, childbearing age without no contraception

          2. Patient with microscopic hematuria, if not excluded that no evidence of neoplastic
             tumor examination

          3. patients with urine culture showing evidence of urinary tract infection 1month prior
             to the study

          4. Accompanied medical problem below

               -  Tuberculosis in urinary system

               -  Bladder cancer, urethral cancer, Prostate cancer

               -  Recurrent cystitis

               -  Anatomical disorder

          5. Patients had prior surgery (bladder augmentation, cystectomy)

          6. Patients with neurologic disorder

          7. Patients with indwelling catheter or intermittent self-catheterization

          8. Patients with psychological problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Soo Choo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-222</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan medical center Institutional review board</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 1, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Soo Choo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>interstitial cystitis</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

